Centro Integral de Investigación de Epilepsia
Descripción general del programa
Research scientists at the Montefiore Einstein Comprehensive Epilepsy Center conduct a broad range of investigations that advance our understanding of epilepsy and other neurological disorders. Whether it is basic science or clinical trials, the researchers at our center are busy collecting data and collaborating with other scientists from all around the world to bring our patients state-of-the-art care and treatment options. Our investigative spectrum spans research that aims to better understand the role of genetics in epilepsy, and examines and evaluates the pathophysiology of seizures and new treatments for patients with this condition, respectively.
Áreas de especialización
Our research programs have identified fundamental differences in the development of epilepsies in infants, children and adolescents. Our expert research team has identified novel treatments as well as biomarkers that show the course of the epilepsies. Simultaneously, we are using advanced computer-based analyses of electrographic recordings to identify the epileptic circuits of drug-resistant epilepsies in order to design effective interventions. We are also focused on improving the quality of life of our children through programs investigating the role of stress and other precipitants that herald a seizure, as well as seizure-induced impairments in the everyday life of children with epilepsy.
Proyectos actuales
EpiBioS4Rx: Estudio bioinformático sobre la epilepsia para la terapia antiepiléptica.
This is a comprehensive prospective study of biomarkers of post-traumatic epileptogenesis. The unique aspects of this study are the early use of cEEG monitoring; depth EEG monitoring; study of both pediatric and adult subjects in a combined study; and a selective clinical phenotype that matches the experimental models.
FEBSTAT: Historia natural y biomarcadores de la epileptogénesis tras un estado epiléptico febril.
Un estudio prospectivo que aborda las relaciones entre el EEG seriado, la resonancia magnética y el seguimiento clínico en una cohorte de niños seguidos desde el momento de la presentación del estado epiléptico febril (EEF).
Translational Platform for Epilepsy Therapy and Biomarker Discovery
This study is an international, multicenter collaboration to look for novel biomarkers that predict a person’s risk for developing post-traumatic epilepsy and for treatments to prevent the condition.
Un sistema de atención médica basado en el aprendizaje para la epilepsia pediátrica
An effort to collect administrative and clinical data entered at the point of care, aggregate and analyze the data across multiple sites, and then regularly report findings with the mission to reduce seizures and their consequences in children with epilepsy.
Retrospective SUDEP in Epilepsy Centers
This is a multicenter international study aiming to identify biomarkers associated with SUDEP (sudden unexpected death in epilepsy).
SMILE: Stress Management Intervention for Living with Epilepsy
SMILE is a clinical trial that evaluates a complex service intervention involving a two-day self-management course with the aim of improving quality of life and clinical outcomes.
Proyecto de Epilepsia Humana
Nuestro equipo de investigación forma parte de una colaboración internacional de médicos y pacientes que buscan respuestas sobre la epilepsia de aparición reciente y la epilepsia resistente al tratamiento.
Ensayos clínicos
Investigar la eficacia y seguridad del carisbamato como tratamiento coadyuvante para las convulsiones asociadas al síndrome de Lennox-Gastaut (SLG) en niños y adultos: un ensayo multicéntrico, doble ciego y controlado con placebo que evalúa la eficacia de un nuevo medicamento anticonvulsivo para el tratamiento de las crisis epilépticas repentinas en niños y adultos con síndrome de Lennox-Gastaut.
Estudio aleatorizado de XEN1101 frente a placebo en crisis epilépticas de inicio focal: un ensayo multicéntrico, doble ciego y controlado con placebo que investiga la eficacia, la seguridad y la tolerabilidad de un nuevo activador de los canales de potasio para el tratamiento de las crisis epilépticas de inicio focal.
